Baseline platelet count and long-term clinical outcomes in patients with acute venous thromboembolism: a prospective cohort study.
Autor: | Stuby J; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. johann.stuby@insel.ch., Stalder O; Department of Clinical Research, CTU Bern, University of Bern, Bern, Switzerland., Limacher A; Department of Clinical Research, CTU Bern, University of Bern, Bern, Switzerland., Righini M; Department of Angiology and Hemostasis, Geneva University Hospital, Geneva, Switzerland., Rodondi N; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.; Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland., Tritschler T; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Méan M; Department of Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland., Aujesky D; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. |
---|---|
Jazyk: | angličtina |
Zdroj: | Annals of hematology [Ann Hematol] 2024 Nov; Vol. 103 (11), pp. 4721-4729. Date of Electronic Publication: 2024 Sep 09. |
DOI: | 10.1007/s00277-024-05982-8 |
Abstrakt: | An abnormal platelet count (PC) is common in acute venous thromboembolism (VTE) but its relationship with clinical outcomes remains ill-defined. We aimed to explore the association between baseline PC and the long-term risk of clinically relevant outcomes in a prospective cohort of 991 patients with acute VTE. We classified patients into four PC groups: very low (< 100 G/l), low (≥ 100 to < 150 G/l), normal (≥ 150 G/l to ≤ 450 G/l), and high (> 450 G/l). The primary outcome was major bleeding (MB), secondary outcomes were recurrent VTE and overall mortality. We examined the association between PC and clinical outcomes, adjusting for confounders, competing risk for mortality, and periods of anticoagulation. After a median follow-up of 30 months, 132 (13%) of patients experienced MB, 122 (12%) had recurrent VTE, and 206 (21%) died. Compared to patients with a normal PC, patients with a very low PC had a sub-distribution hazard ratio (SHR) for MB of 1.23 (95% confidence interval [CI] 0.52-2.91) and those with a high PC a SHR of 1.87 (95%CI 0.82-4.29). Patients with a low PC had a twofold increased VTE recurrence risk (SHR 2.05, 95%CI 1.28-3.28). Patients with low and very low PC had a hazard ratio for mortality of 1.43 (95%CI 0.99-2.08) and of 1.55 (95%CI 0.80-2.99), respectively. Our findings do not suggest a consistent relationship between baseline PC and long-term clinical outcomes in patients with VTE. (© 2024. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: |